NRx Pharmaceuticals (NRXP) News Today → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free NRXP Stock Alerts $3.14 +0.02 (+0.64%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineWhy Is NRX Pharmaceuticals (NRXP) Stock Down 29% Today?investorplace.com - April 18 at 8:56 AMNRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stockfinance.yahoo.com - April 18 at 8:39 AMNRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirementfinance.yahoo.com - April 18 at 8:39 AMNRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirementprnewswire.com - April 18 at 8:32 AMNRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stockprnewswire.com - April 18 at 8:30 AMNRx Pharmaceuticals: New Data Demonstrates No Impact Of NRX-101 On Gut Or Vaginal Floramarkets.businessinsider.com - April 17 at 10:07 AMNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infectionsfinance.yahoo.com - April 17 at 10:07 AMNRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)prnewswire.com - April 15 at 8:30 AMNRx Pharmaceuticals Advances in Breakthrough Bipolar Depression Treatmentmsn.com - April 14 at 7:15 PMShort Interest in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Declines By 88.6%marketbeat.com - April 10 at 9:59 PMNRx Pharma Achieves Data-lock In Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression Studymarkets.businessinsider.com - April 8 at 11:23 AMNRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depressionprnewswire.com - April 8 at 8:30 AMNew Brain Cap Lets People Play Video Games With Their Mindsmsn.com - April 3 at 9:19 PMRep. Raúl Grijalva announces cancer diagnosisca.news.yahoo.com - April 3 at 4:56 AMWoman, 23, diagnosed with cancer after thinking she was bloated with irritable bowel syndromeca.news.yahoo.com - April 3 at 4:56 AMAlberta creating 2 mental health and addictions organizations, including Crown corporationca.news.yahoo.com - April 2 at 6:55 PMThere’s Nothing Wrong With Having Hooded Eyesmsn.com - April 2 at 6:55 PMA dietitian explains how a 'diet break' can make it easier to lose weight and keep it offmsn.com - April 2 at 6:55 PMNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - April 2 at 1:55 PMmarketbeat.com - April 2 at 6:01 AMNRx Pharmaceuticals reports Q4 resultsmsn.com - April 1 at 12:48 PMNRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateprnewswire.com - April 1 at 8:28 AMNRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listingfinanznachrichten.de - March 28 at 1:25 PMNRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlightsfinance.yahoo.com - March 28 at 8:23 AMNRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listingprnewswire.com - March 28 at 8:00 AMNRx Pharmaceuticals Set to Unveil Fourth Quarter and Full Year 2023 Financial Resultsmsn.com - March 27 at 10:22 PMUPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024finance.yahoo.com - March 27 at 1:30 AMNRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UKfinance.yahoo.com - March 25 at 4:39 PMNRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholdersfinanznachrichten.de - March 22 at 10:45 AMNRx Pharmaceuticals (NRXP) Set to Announce Quarterly Earnings on Thursdaymarketbeat.com - March 22 at 10:28 AMNRx Pharmaceuticals Forges Key Alliances to Bolster Ketamine Supply for Mental Health Treatmentmsn.com - March 21 at 7:06 PMNRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024prnewswire.com - March 21 at 4:02 PMNRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholdersprnewswire.com - March 21 at 1:57 PMNRx Pharma to distribute HOPE Therapeutics stock, pay Ketamine royalty to holdersmsn.com - March 18 at 10:24 AMNRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholdersfinance.yahoo.com - March 18 at 10:24 AMNRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Salesfinanznachrichten.de - March 12 at 11:18 AMNRx unveils plan to battle naked short selling in sharesmsn.com - March 12 at 11:18 AMNRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Salesprnewswire.com - March 12 at 7:49 AMNRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)prnewswire.com - March 11 at 8:30 AMNRXP Apr 2024 2.000 callfinance.yahoo.com - March 9 at 10:52 PMNRXP Apr 2024 1.000 callfinance.yahoo.com - March 7 at 1:38 PMNRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depressionprnewswire.com - March 4 at 8:30 AMPositive Signs As Multiple Insiders Buy NRx Pharmaceuticals Stockfinance.yahoo.com - March 2 at 12:55 PMNRx Pharmaceuticals announces $1M purchase agreementmsn.com - March 1 at 6:14 PMNRx Pharmaceuticals Receives Approx. $1.0 Mln From Existing Investor - Quick Factsmarkets.businessinsider.com - March 1 at 1:14 PMNRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per Sharefinance.yahoo.com - March 1 at 1:14 PMNRx Pharma Announces Pricing Of $1.5 Mln Share Offering, Stock Falls 32%markets.businessinsider.com - February 27 at 10:09 AMNRx Pharmaceuticals, Inc. Announces Pricing of $1.5 Million Underwritten Public Offering of Common Stock Together with investor Commitment for Additional $1 millionprnewswire.com - February 27 at 8:54 AMWhy Is NRX Pharmaceuticals (NRXP) Stock Down 23% Today?investorplace.com - February 27 at 8:31 AMNRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stockprnewswire.com - February 26 at 4:01 PM Get NRx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRXP and its competitors with MarketBeat's FREE daily newsletter. Email Address “Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers. Find out why right here (and see what you can do to get in too with just a few dollars). NRXP Media Mentions By Week NRXP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NRXP News Sentiment▼0.030.41▲Average Medical News Sentiment NRXP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NRXP Articles This Week▼12▲NRXP Articles Average Week Get NRx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRXP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Daré Bioscience News Aprea Therapeutics News Lexaria Bioscience News Spruce Biosciences News ImmunoPrecise Antibodies News Acurx Pharmaceuticals News Theratechnologies News CASI Pharmaceuticals News VYNE Therapeutics News Acasti Pharma News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NRXP) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
